This study provides the proof of concept that paralogous TRIM40 expression serves as a master pathological driver of chronic inflammation in the gut, and thus may be a potential biomarker or therapeutic target to limit IBD initiation and development. This evidence concerns the gene TRIM40 and inflammatory bowel disease.